This work was undertaken by the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (APM) as a demonstration project in developing clinical guidelines relevant to palliative care from a pragmatic approach to literature review and grading of clinical evidence. CANCERLIT and Embase were searched for relevant papers written in English, published since 1980. Each study identified was rated against agreed criteria for levels of evidence. Most studies were not specifically designed to define speed of response, and were not undertaken in palliative care patients. Thus, careful reading and grading of each study was necessary. Sufficient evidence was identified to make recommendations for clinical practice in a palliative care population of patients, and areas for future research have been identified. Bisphosphonates appear to have a role in managing pain from metastases which has been refractory to conventional analgesic management and where oncological or orthopaedic intervention is delayed or inappropriate.
Abrams HL, Spiro R, Goldstein N. Metastases in carcinomas: analysis of 1000 autopsied cases. Cancer1950; 23: 74–85.
2.
Pereira J, Mancini I, Walker P. The role of bisphosphonates in malignant bone pain: a review. J Palliat Care1998; 14(2): 25–36.
3.
Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidencebased review. J Clin Oncol1998; 16: 1218–1225.
4.
Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain1998; 78: 157–169.
5.
Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest1986; 89: 2S–3S.
6.
McCloskey EV, MacLennan ICM, Drayson M et al. Efficacy of clodronate on progressing skeletal disease in multiple myelomatosis. N Engl J Med1995; 31A: S162.
7.
Berenson JR, Lichenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med1996; 334: 488–493.
8.
Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol1991; 9: 1397–1402.
9.
Lahtinen R, Laasko M, Palva I et al. Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet1992; 340: 1049–1052.
10.
Paterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol1993; 11: 59–65.
11.
Kanis JA, Powles T, McCloskey AHG, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone1996; 19: 663–667.
12.
van Holten-Vertzantvoort ATM, Zwinderman AH, Aaronson NK et al. The effect of supportive pamidronate treatment on aspects of quality of life of patents with advanced breast cancer. Eur J Cancer1991; 27: 544–549.
13.
Coleman RE, Houston S, Purohit OP et al. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur J Cancer1998; 34: 820–824.
14.
Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised, controlled trial. J Clin Oncol1996; 14: 2552–2559.
15.
Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med1996; 335: 1785–1791.
16.
Lipton A, Glover D, Harvey H et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol1994; 5: S1–S35.
17.
Elomaa I, Kylmala T, Temmela T et al. Effect of oral clodronate on bone pain–a controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol1992; 24: 159–166.
18.
Smith JA. Palliation of painful bone metastases from prostate cancer using disodium etidronate: results of a randomised, prospective, double-blind, placebo-controlled study. J Urol1989; 141: 85–87.
19.
Strang P, Nilsson S, Brandsteads S et al. The analgesic efficacy of clodronate compared with placebo in patients with painful metastases from prostate cancer. Anticancer Res1997; 17: 4717–4721.
20.
Kylmala T, Taube T, Tammela TL et al. Concomitant intravenous and oral clodronate in the relief of bone pain–a double-blind, placebo controlled study in patients with prostate cancer. Br J Cancer1997; 76: 939–942.
21.
Adami S. Bisphosphonates in prostate carcinoma. Cancer1997; 80(8 suppl): 1674–1679.
22.
Ernst SD, MacDonald N, Paterson A et al. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage1992; 7: 4–11.
23.
Ernst DS, Brasher P, Hagen N et al. Controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. Proc Am Soc Clin Oncol1994; 1: 1478.
24.
Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol1995; 13: 2427–2430.
25.
Ernst DS, Brasher P, Hagen N et al. A randomised controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage1997; 13: 319–326.
26.
Vinholes JJ, Guo C-Y, Purohit OP et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer1996; 73: 1089–1095.
27.
Purohit OP, Anthony C, Radstone CR et al. High dose intravenous pamidronate for metastatic bone pain. Br J Cancer1994; 70: 554–558.
28.
Vinholes JJF, Prakash Purokit O, Abbey ME, Eastell R and Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol1997; 8: 1243–1250.
29.
Coleman RE, Purohit OP, Black C et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol1999; 10: 311–316.
30.
Ghose K, Waterworth R, Trolove P et al. Uveitis associated with pamidronate. Aust NZ J Med1994; 24: 320.
31.
van Holten-Verzantvoort A, Kroon H, Bijvoet F. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol1993; 11: 491–498.
32.
Cascinu S, Casadei V, Del Ferro E et al. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormone and/or chemotherapy. Support Care Cancer1996; 4: 31–33
